173 related articles for article (PubMed ID: 22584245)
1. Cholesteryl ester transfer protein and ATP-binding cassette transporter A1 genotype alter the atorvastatin and simvastatin efficacy: time for genotype-guided therapy?
Kolovou G; Kolovou V; Mihas C; Giannakopoulou V; Vasiliadis I; Boussoula E; Kollia A; Boutsikou M; Katsiki N; Mavrogeni S
Angiology; 2013 May; 64(4):266-72. PubMed ID: 22584245
[TBL] [Abstract][Full Text] [Related]
2. Differential effect of ATP binding cassette transporter A1 R219K and cholesteryl ester transfer protein TaqIB genotypes on HDL-C levels in overweight/obese and non-obese Chinese subjects.
Huang Y; Wu Y; Liu R; Fan P; Zhang J; Wang F; Luo X; Liu Y; Liu B; Bai H
Acta Cardiol; 2011 Apr; 66(2):231-7. PubMed ID: 21591583
[TBL] [Abstract][Full Text] [Related]
3. Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes.
van Venrooij FV; Stolk RP; Banga JD; Sijmonsma TP; van Tol A; Erkelens DW; Dallinga-Thie GM;
Diabetes Care; 2003 Apr; 26(4):1216-23. PubMed ID: 12663600
[TBL] [Abstract][Full Text] [Related]
4. Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy.
Poduri A; Khullar M; Bahl A; Sehrawat BS; Sharma Y; Talwar KK
DNA Cell Biol; 2010 Oct; 29(10):629-37. PubMed ID: 20578904
[TBL] [Abstract][Full Text] [Related]
5. Relationship between the cholesterol ester transfer protein TaqIB polymorphism and the lipid-lowering effect of atorvastatin in patients with coronary atherosclerotic heart disease.
Li J; Zhang L; Xie NZ; Deng B; Lv LX; Zheng LQ
Genet Mol Res; 2014 Mar; 13(1):2140-8. PubMed ID: 24737438
[TBL] [Abstract][Full Text] [Related]
6. Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study).
Robinson JG; Ballantyne CM; Grundy SM; Hsueh WA; Parving HH; Rosen JB; Adewale AJ; Polis AB; Tomassini JE; Tershakovec AM
Am J Cardiol; 2009 Jun; 103(12):1694-702. PubMed ID: 19539078
[TBL] [Abstract][Full Text] [Related]
7. [Influence of CETP gene -629C/A polymorphism on the efficacy of atorvastatin treatment and clinical outcome].
Gao J; Cong HL; Mao YM; Liu Y; Zhang N; Chen Q; Liu T; Cui R
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Oct; 30(5):553-8. PubMed ID: 24078569
[TBL] [Abstract][Full Text] [Related]
8. Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low-density lipoprotein-cholesterol--a multinational, multicenter, double-blind study.
Wu CC; Sy R; Tanphaichitr V; Hin AT; Suyono S; Lee YT
J Formos Med Assoc; 2002 Jul; 101(7):478-87. PubMed ID: 12353340
[TBL] [Abstract][Full Text] [Related]
9. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM
J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151
[TBL] [Abstract][Full Text] [Related]
10. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
Stender S; Schuster H; Barter P; Watkins C; Kallend D;
Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of atorvastatin compared with simvastatin in patients with hypercholesterolemia.
Farnier M; Portal JJ; Maigret P
J Cardiovasc Pharmacol Ther; 2000 Jan; 5(1):27-32. PubMed ID: 10687671
[TBL] [Abstract][Full Text] [Related]
12. Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice.
de Haan W; van der Hoogt CC; Westerterp M; Hoekstra M; Dallinga-Thie GM; Princen HM; Romijn JA; Jukema JW; Havekes LM; Rensen PC
Atherosclerosis; 2008 Mar; 197(1):57-63. PubMed ID: 17868678
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetic study of cholesteryl ester transfer protein gene and simvastatin treatment in hypercholesterolaemic subjects.
Anagnostopoulou K; Kolovou G; Kostakou P; Mihas C; Mikhailidis D; Cokkinos DV
Expert Opin Pharmacother; 2007 Oct; 8(15):2459-63. PubMed ID: 17931083
[TBL] [Abstract][Full Text] [Related]
14. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.
Robinson JG; Ballantyne CM; Hsueh WA; Rosen JB; Lin J; Shah AK; Tomassini JE; Lowe RS; Tershakovec AM
J Clin Lipidol; 2013; 7(4):292-303. PubMed ID: 23890516
[TBL] [Abstract][Full Text] [Related]
15. Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals.
Fu Q; Li YP; Gao Y; Yang SH; Lu PQ; Jia M; Zhang LR
Eur J Clin Pharmacol; 2013 Jun; 69(6):1269-74. PubMed ID: 23263738
[TBL] [Abstract][Full Text] [Related]
16. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
[TBL] [Abstract][Full Text] [Related]
17. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.
Illingworth DR; Crouse JR; Hunninghake DB; Davidson MH; Escobar ID; Stalenhoef AF; Paragh G; Ma PT; Liu M; Melino MR; O'Grady L; Mercuri M; Mitchel YB;
Curr Med Res Opin; 2001; 17(1):43-50. PubMed ID: 11464446
[TBL] [Abstract][Full Text] [Related]
18. The effect of APOE, CETP, and PCSK9 polymorphisms on simvastatin response in Thai hypercholesterolemic patients.
Wanmasae S; Sirintronsopon W; Porntadavity S; Jeenduang N
Cardiovasc Ther; 2017 Dec; 35(6):. PubMed ID: 28851085
[TBL] [Abstract][Full Text] [Related]
19. [Effects of genetic variations of cholesteryl ester transfer protein on atorvastatin treatment efficacy and clinical outcomes in patients with coronary artery disease].
Gao J; Cong HL; Mao YM; Liu Y; Zhang N; Chen Q; Liu T; Cui RZ
Zhonghua Yi Xue Za Zhi; 2013 Jul; 93(28):2195-9. PubMed ID: 24169327
[TBL] [Abstract][Full Text] [Related]
20. Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study.
Goldberg RB; Guyton JR; Mazzone T; Weinstock RS; Polis A; Edwards P; Tomassini JE; Tershakovec AM
Mayo Clin Proc; 2006 Dec; 81(12):1579-88. PubMed ID: 17165637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
